Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Memantine

An NMDA glutamate receptor antagonist used in moderate to severe Alzheimer's disease: synthesised in the 1960s, it was approved in Europe in 2002 and in the United States in 2003. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.

Did you know?It was first made as a possible antidiabetic, but it did not lower blood sugar; its cage-like core, adamantane, is named after diamond because it repeats diamond's arrangement of carbon atoms.

MemantineGo to the active ingredient →
MemantineActive ingredientMemantineCat. No. P-M043-001CAS 19982-08-2

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.